Summary
Gilead Sciences, Inc. (GILD) has entered into a $1.25 billion Amended and Restated Credit Agreement, effective December 18, 2007. This new agreement, which amends and restates a prior credit facility from December 2005, provides enhanced borrowing capacity for general corporate purposes and working capital. The agreement allows for revolving credit loans, swing line loans, and letters of credit, with an interest rate structure based on LIBOR plus a margin or a base rate. An important feature of this update is the potential for an additional $500 million in aggregate commitments, subject to lender approval and specific request conditions. The credit facility has a maturity date of December 17, 2012, and offers flexibility for early repayment without penalty, barring certain reimbursement costs. This move demonstrates Gilead's proactive financial management and its ability to secure substantial credit lines to support ongoing operations and strategic initiatives.
Key Highlights
- 1Gilead Sciences entered into a $1.25 billion Amended and Restated Credit Agreement on December 18, 2007.
- 2The new credit agreement amends and restates a previous agreement from December 2005.
- 3Proceeds from the loans are designated for working capital requirements and general corporate purposes.
- 4The agreement includes a sub-facility for swing line loans and letters of credit.
- 5Interest rates are tied to either LIBOR plus a margin (0.20%-0.32%) or a base rate.
- 6Gilead has the option to request an increase in commitments by up to $500 million prior to the fourth anniversary of the closing date.
- 7The credit facility matures on December 17, 2012, with flexibility for early repayment.